November 19, 2020
EFPIA Japan Chair Heike Prinz Multinational pharma companies are seriously reconsidering “if and when to include Japan into their global drug development” after the country’s drastic pricing reform in 2018 eroded the predictability of their business in the market, EFPIA...read more